Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 556

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 556
---
  
     1,480,208 
  
    2014 Equity
Incentive Plan 
     380,132  
    $5.78  
     — 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 
  
    Total 
     899,924  
    $3.59  
     1,480,208 

Item
6. [Reserved.]

Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This
section presents management’s perspective on our financial condition and results of operations. The following discussion and analysis
(the “MD&A”) is intended to highlight and supplement data and information presented elsewhere in this Annual Report.
The MD&A is also intended to provide you with information that will assist you in understanding our consolidated financial statements,
the changes in key items in those consolidated financial statements from year to year, and the primary factors that accounted for those
changes. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may
not be indicative of our future financial outcomes. In addition to historical information, this discussion contains forward-looking statements
that involve risks, uncertainties, and assumptions that could cause the Company’s financial results to differ materially from management’s
expectations. Factors that could cause such differences are discussed in the “Cautionary Note Regarding Forward-Looking Statements”
section of this Annual Report and in the “Risk Factors” in this Annual Report.

 54 

Our
MD&A is organized as follows:

    ●
    Company
    Overview – Discussion of our business plan and strategy to provide context for the remainder of the MD&A.

    ●
    Results
    of Operations – Analysis of our financial results comparing the year ended December 31, 2024, to the year ended December
    31, 2023.

    ●
    Liquidity
    and Capital Resources – Analysis of changes in our cash flows and discussion of our financial condition and potential sources
    of liquidity.

    ●
    Critical
    Accounting Estimates – Accounting estimates are those estimates made in accordance with U.S. generally accepted accounting
    principles (“GAAP”) that we believe are important to understanding the assumptions and judgments incorporated in our
    reported financial results and forecasts.

Company
Overview

Business

We develop noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry